| [1] |
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumours in the United States[J]. JAMA Oncol, 2017, 3(10):1335-1342.
|
| [2] |
Riihimäki M, Hemminki A, Sundquist K, et al. The epidemiology of metastases in neuroendocrine tumors[J]. Int J Cancer, 2016, 139(12):2679-2686.
|
| [3] |
WHO Classification of Tumours Editorial Board. Digestive system tumours, WHO classification of tumours[M]. 5th Edition. Lyon: International Agency for Research on Cancer Press, 2019.
|
| [4] |
Frilling A, Li J, Malamutmann E, et al. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease[J]. Br J Surg, 2009, 96(2):175-184.
|
| [5] |
Mazzaferro V, Sposito C, Coppa J, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors[J]. Am J Transplant, 2016, 16(10):2892-2902.
|
| [6] |
Sham JG, Ejaz A, Gage MM, et al. The impact of extent of liver resection among patients with neuroendocrine liver metastasis:an international multi-institutional study[J]. J Gastrointest Surg, 2019, 23(3):484-491.
|
| [7] |
Ejaz A, Reames BN, Maithel S, et al. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis:a multi-institutional analysis[J]. HPB, 2018, 20(3):277-284.
|
| [8] |
Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors[J]. Surgery, 2018, 163(1):218-225.
|
| [9] |
Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term followup in 123 patients[J]. Med Oncol, 2011, 28 Suppl 1:S286-290.
|
| [10] |
Vogl TJ, Naguib NN, Zangos S, et al. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation[J]. Eur J Radiol, 2009, 72(3):517-528.
|
| [11] |
Christante D, Pommier S, Givi B, et al. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy[J]. Surgery, 2008, 144(6):885-893.
|
| [12] |
Egger ME, Armstrong E, Martin RC 2nd, et al. Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: a multi-institutional analysis[J]. J Am Coll Surg, 2020, 230(4):363-370.
|
| [13] |
Rinke A, Wittenberg M, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival[J]. Neuroendocrinology, 2017, 104(1):26-32.
|
| [14] |
Wolin EM, Pavel M, Cwikla JB, et al. Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): the CLARINET extension study[J]. J Clin Oncol, 2017, 35(15_suppl):4089.
|
| [15] |
Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phaseⅢ RADIANT-3 study[J]. J Clin Oncol, 2016, 34(32):3906-3913.
|
| [16] |
Kulke MH, Ruszniewski P, Van Cutsem E, et al. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial[J]. Ann Oncol, 2017, 28(6):1309-1315.
|
| [17] |
Faivre S, Niccoli P, Castellano D, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phaseⅢ randomized study[J]. Ann Oncol, 2017, 28(2):339-343.
|
| [18] |
Rinzivillo M, Fazio N, Pusceddu S, et al. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: a real-world study[J]. Pancreatology, 2018, 18(2):198-203.
|
| [19] |
Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(11):1500-1512.
|
| [20] |
Xu J, Shen L, Bai C, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(11):1489-1499.
|
| [21] |
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors[J]. N Engl J Med, 2017, 376(2):125-135.
|
| [22] |
Kunz PL, Catalano PJ, Nimeiri H, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: a trial of the ECOG-ACRIN cancer research group (E2211) [J]. J Clin Oncol, 2018, 36(15 suppl):e4004.
|
| [23] |
Strosberg J, Mizuno N, Doi T, et al. Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase Ⅱ KEYNOTE-158 study[J]. Clin Cancer Res, 2020, 26(9):2124-2130.
|